RATE-AF Trial

Dr. Michael Thibert presented the RATE-AF Trial, which is a prospective, randomized, open-label, blinded, endpoint trial comparing the use of digoxin and beta-blockers as initial rate control therapy for permanent atrial fibrillation. This trail was published in JAMA this past December.